

News Release

CYBERDYNE, INC.

Shisei Datum, Ltd.

5 October, 2017

**CYBERDYNE, INC. and Shisei Datum Ltd. form a business and capital alliance towards  
the society of good health and longevity**

**~Measurement and control of blood vessel information to reinforce and speed up business  
on prevention of lifestyle-related diseases~**

CYBERDYNE, INC. (Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai [the “Company”] ) and Shisei Datum Ltd. (Machida, Tokyo, CEO: Yukiyoshi Saito [Shisei Datum] ) announce that they have formed a capital tie-up (CYBERDYNE will make an investment in Shisei Datum) and a business alliance to reinforce and accelerate the business on prevention of lifestyle-related diseases, such as stroke, heart attack and so on, through measurement and control of blood vessel information.

In the hyper-aging society, importance of preventing diseases caused by aging is increasing. In Japan, stroke and cardiovascular diseases such as heart attack account for 30% of deaths or aftereffect that forces patients to be bed ridden. A major cause of these diseases is progression of arteriosclerosis due to lifestyle-related diseases. That means, prevention of lifestyle-related diseases through daily measurement and control of blood vessel information is crucial for people to live long and healthily.

The two companies aim to collaborate further in medicine, long-term care and living support (at home and in work environments) and various other fields to achieve the society of good health and longevity. Shisei Datum has sufficient knowhow and excellent track records of design, development and manufacture of medical electronic sphygmomanometer. The Company has been developing Vital Sensor, a palm-size measuring device of arteriosclerosis and irregular pulses. The Company completed its preliminary consultation with the Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”) and commenced preparing for various application processes to obtain the medical device approval for the Vital Sensor. Its coordination with Shisei Datum would upgrade the device by installing additional functions

that would reinforce and accelerate the business of the device. Vital Sensor would allow people to be connected to the Internet of Humans (IoH), regardless whether it is used at a hospital, home or a workplace. It will become the core device to prevent lifestyle-related diseases such as stroke, heart attack and so on. With this alliance, the two companies aim to contribute to the realization of the society of good health and longevity where everyone could live long, comfortably and healthily, while challenging to solve social problems such as the impending situation of the health financing and burdening care.

<About CYBERDYNE, INC.>

Since its establishment as a venture company from the University of Tsukuba in 2004, CYBERDYNE, INC. has promoted the comprehensive development of various Cybernic systems (Cybernic devices, Cybernic interfaces, etc.) that utilize Cybernic technology from research and development to social implementation, aiming to tackle the various issues facing society. The Company has developed business in the fields of medicine, welfare and daily living (including the work environment), and its main product Robot Suit HAL® is widely distributed not only in the medical and welfare fields but also in care support and labor support fields. In addition, new products such as Transport Robots and Cleaning Robots equipped with artificial intelligence and environment recognition functions, HAL Lumbar Type that reduces the load and stress on the lower back, smaller-sized HAL (Single-Joint Type), vital sensors for detecting arteriosclerosis and arrhythmia measurements, etc. are continuously being developed.

For more details, please refer to the following website: [www.cyberdyne.jp/eng/](http://www.cyberdyne.jp/eng/)

<About Shisei Datum Ltd.>

Shisei Datum Ltd. was founded in 1988 by three TV engineers as a company that undertook customized development of electronic equipments such as wireless data communication devices, teleconference system, and blood pressure monitors. Having focused on research and development of noninvasive vascular biomarker, we collaborated with the National Institute of Advanced Industrial Science and Technology, RIKEN and other national research institutes since 2004, and succeeded in developing two innovative vascular indexes that evaluate the risk of arterial sclerosis —API (Arterial Pulse Volume Index) and AVI (Arterial Velocity Pulse Index), which can be measured simply at one-side of the upper arm in a sitting position. Having obtained pharmaceutical approval in 2012, our equipments featuring these



two indexes are being introduced to medical facilities in Japan and abroad as novel device in the healthcare field for the aging society. For details, please refer to <http://www.shisei-d.co.jp/>.